Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.

Neuropsychiatr Dis Treat · 2015 · PMC4445870 · PMID 26056453

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Eleven percent of interferon-treated patients and 8% of alemtuzumab-treated patients had disability progression; however, the difference between the groups did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.